Great find kevli…..he referred to Anavex 2-73 trial as an important first step in application of precision medicine to Alzheimer's. And he was speaking in Spain...where the PD trial is using the precision medicine approach to PD. And in his talk he stressed the need for a broad application of genetic based precision medicine...not only to cancer but also to a wide range of CNS diseases. Very worthwhile to listen to. He saved discussion of the Anavex 2-73 trial to near THE END OF HIS TALK, TO SUM UP WHAT HE WAS IT WAS ALL ABOUT!
Thanks kevli. HH is doing some heavy lifting here IMo. Downplaying BIIB’s approach and supporting AVXL’s in a roundabout way. Wont be long now, partnership tied to trial starts and or FDA approvals will be in the Billions.